Spexis AG

Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera

Spexis announces closing of sale of preclinical antibiotics program to Basilea

Spexis announces sale of preclinical antibiotics program to Basilea

Spexis is Granted Debt-Restructuring Moratorium

Spexis Provides Update Regarding Debt-Restructuring Moratorium

Spexis to file an application for a debt-restructuring moratorium